胡元晶个人简介

作为天津医科大学、南开大学博士研究生导师，天津市中心妇产科医院党委书记、主任医师，国务院特殊津贴专家，2014年度“131”创新型人才培养工程第一层次人选，2017年度“131”创新团队带头人，首届天津名医、首批高层次人才津门医学英才，2021年度被评为天津市卫生健康系统优秀共产党员，2020年12月获中华人民共和国国务院政府特殊津贴掌握妇科恶性肿瘤的手术及放化疗等综合治疗手段,擅长微创手术，开展新技术并填补多项天津市的空白。发表论文40余篇，其中SCI收录20余篇，获得发明专利2项，主编出版专著2部。申请科研项目20余项。

主要研究方向

主要研究方向为妇科恶性肿瘤。与国际前沿接轨，对肿瘤患者采用规范化、恰当的综合治疗，对罕见疑难病例能够为患者制定最优化治疗方案。熟练掌握妇科各类四级手术，自2011年美国访问归来后率先在我院开展妇科恶性肿瘤腹腔镜治疗，如腹腔镜下宫颈癌广泛全子宫切除术+盆腔淋巴结切除术，腹腔镜下子宫内膜癌分期手术和早期卵巢癌分期手术，以及腹腔镜下保留神经功能的广泛全子宫切除手术，该项技术于2013年填补天津市空白，达到国内先进水平。

宫颈癌是女性第二大常见恶性肿瘤,高危型HPV持续感染是罹患宫颈癌的直接原因，不同地区高危型HPV感染可能存在差异，且不同型别高危型HPV的致病作用有所不同，近年来研究应用焦磷酸测序技术检测高危型HPV，在宫颈癌及癌前病变筛查中起到非常重要的作用。通过定位、定量检测位于HPVl6 L1基因3’端和LCR基因的甲基化位点的甲基化水平，了解HPVl6甲基化与其致病性的关系。对宿主抑癌基因表现遗传学研究，进一步揭示高危型HPV感染宫颈癌发生的内在原因，有可能为宫颈癌筛查早期诊断或有效治疗提供新方法。

代表性学术成果

1．Tang X , Li N, Hu Y*. Prognosis and adjuvant chemotherapy for patients with malignant peritoneal cytology in early-stage non-endometrioid endometrial cancer，European Journal of Surgical Oncology ，2023.9，IF:3.8

2．Tang X , Li N, Hu Y*.The role of TCGA molecular classification in clear cell endometrial carcinoma,Frontiers in Oncology  2023.6 IF:4.7

3．SiyangLiu,LiyingYao,YumengWang,YiLi,YanjuJia,YueyueYang,NaLi,Yuanjing Hu, DelingKong, XianhaoDong, KaiWang, MeifengZhu. Immunomodulatory hybrid micro-nanofiber scaffolds enhance vascular regeneration. Bioactive Materials.2023,March,464-482. IF=16.874 

4．靶向叶酸受体a的抗体偶联物治疗卵巢癌研究进展，唐欣月，胡元晶，现代妇产科进展2022年7月第31卷第7期

5．Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022;40:2436-46. IF=50.717

6．Zeng J, Sun P, Ping Q, Jiang S, Hu Y*. Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy. PLoS One 2022;17:e0266001. （通讯作者）IF=3.752

7．Pu G, Jiang S, Yang Z, Hu Y, Liu Z. Deep reinforcement learning for treatment planning in high-dose-rate cervical brachytherapy. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) 2022;94:1-7. IF=3.119

8．Zhang X, Chen Y, Wang X, Zhang Z, Wang J, Shen Y, Hu Y, Wu X. NINJ1 triggers extravillous trophoblast cell dysfunction through blocking the STAT3 signaling pathway. Genes & genomics 2022;44:1385-97. IF=2.164

9．Li J, Zhang Z, Hu Y*, Wei Q, Shao X. Circ_0039569 contributes to the paclitaxel resistance of endometrial cancer via targeting miR-1271-5p/PHF6 pathway. Anti-cancer drugs 2022;33:883-92. （通讯作者）IF=2.389

10．Pu G, Jiang S, Yang Z, Hu Y, Liu Z. A novel ultrasound probe calibration method for multimodal image guidance of needle placement in cervical cancer brachytherapy. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) 2022;100:81-89. IF=3.119

11．Li H, Sun L, Zhuang Y, Tian C, Yan F, Zhang Z, Hu Y*, Liu P. Molecular mechanisms and differences in lynch syndrome developing into colorectal cancer and endometrial cancer based on gene expression, methylation, and mutation analysis. Cancer causes & control : CCC 2022;33:489-501. （通讯作者）IF=2.532

12．Li, P., Y. Bai, B. Shan, Hu Y*  et al. Exploration of Potential Diagnostic Value of Protein Content in Serum Small Extracellular Vesicles for Early-Stage Epithelial Ovarian Carcinoma[J]. Front Oncol, 2021. 11:707658. （通讯作者）IF=5.738

13．Sun P, Shen Y, Wang T, He Y, Zhang Y, Tian W, Yang B and Hu Y*. Distinct clinical and genetic mutation characteristics in sporadic and Lynch syndrome-associated endometrial cancer in a Chinese population. Cancer epidemiology 2021; 73: 101934. （通讯作者）IF=2.890

14．Yang B, Wang T, Li N, Zhang W and Hu Y*. The High Expression of RRM2 Can Predict the Malignant Transformation of Endometriosis. Advances in therapy 2021; 38: 5178-5190. （通讯作者）IF=4.070

15．Na Li, Yuanjing Hu, Xinying Zhang, Yixin Liu, Ya He, Ate G J van der Zee, Ed Schuuring , G Bea A Wisman. DNA methylation markers as triage test for the early identification of cervical lesions in a Chinese population. Int J of Cancer. 2021,148(7):1768-1777. IF=7.316

16．Wang W, Zhang W, Hu Y*. Identification of keygenes, miRNAs and miRNA-mRNA regulatory pathways for chemotherapy resistance in ovarian cancer. PeerJ 2021;9:e12353.（通讯作者）IF=3.061

17．Zhuang Y, Wang H, Jiang D, Li Y, Feng L, Tian C, Pu M, Wang X, Zhang J, Hu Y*, Liu P. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer 2021;21:380. （通讯作者）IF=4.638

18．Yu N, Hu Y*, Cui H, Cheng L, Chen X. Evaluating pentraxin-3 and hypersensitivity CRP expression in obese pregnancies. Taiwanese journal of obstetrics & gynecology 2021;60:816-20. （通讯作者）IF=1.944

19．Zhang X, Fan J, Chen Y, Wang J, Song Z, Zhao J, Li Z, Wu X, Hu Y*. Cytogenetic Analysis of the Products of Conception After Spontaneous Abortion in the First Trimester. Cytogenetic and genome research 2021;161:120-31. （通讯作者）IF=1.941

20．Zheng H, Gao Y, Guo H, Li L, Li Q, Cui H, Lin A, Sun L, Hu Y, Kang S, Duan W, Pan L, Wang S, Yang Y, Li Y, Kong W, Xiang Y, Tian X, Ling B, Ha C, Bai W. Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter Study. Molecular cancer therapeutics 2021;20:1735-42. IF=6.009

21．18. Zhang XP, Zhang YF, Shi R, Zhang YJ, Zhang XL, Hu XM, Hu XY, Hu YJ*. Pregnancy outcomes of infertile women with ultrasound-diagnosed adenomyosis for in vitro fertilization and frozen-thawed embryo transfer. Arch Gynecol Obstet 2021;304:1089-96. （通讯作者）IF=2.493

22．19. Ping Q, Zeng J, Sun P, Qu P, Jiang S, Hu Y*. Efficacy of preoperative brachytherapy for controlling vaginal bleeding in early-stage cervical cancer: a retrospective study. Transl Cancer Res 2021;10:3259-67. （通讯作者）IF=0.496

23．Gao Y, Zhang X, Wang T, Zhang Y, Wang Q and Hu Y*. HNRNPCL1, PRAMEF1, CFAP74, and DFFB: Common Potential Biomarkers for Sporadic and Suspected Lynch Syndrome Endometrial Cancer. Cancer Manag Res 2020; 12: 11231-11241. （通讯作者）IF=3.602

24．He Y, Wang T, Li N, Yang B and Hu Y*. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2020; 99: e19281. （通讯作者）IF=1.817

25．Na Li, Peng Mi, Yuanjing Hu*. Construction of dysregulated long non-coding RNA-associated competing endogenous RNA network in uterine corpus endometrial carcinoma. Transl Cancer Res. 2020,9(2): 669-682. （通讯作者） IF=0.496

26．Zeng J, Qu P, Hu Y, Sun P, Qi J, Zhao G, Gao Y. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB: A single center retrospective study. Medicine (Baltimore) 2020;99:e19714. IF=1.817

27．Zhang H, Hu Y*, Zhu Y, Chen X. Facing the SARS-CoV-2 Outbreak: What Should Obstetricians and Gynecologists Do? Disaster medicine and public health preparedness 2020;14:e19-e21. （通讯作者）IF=5.556

28．Wang Q, Hu Y*, He Y, Wang T, Ghimire P. Glassy cell carcinoma of cervix: an analysis for 20 cases and literatures review. Transl Cancer Res 2020;9:2357-62. （通讯作者） IF=0.496

29．Zhang H, Wang X, Xu J, Zhu Y, Chen X, Hu Y. IL-18 and IL-18 binding protein concentration in ovarian follicular fluid of women with unexplained infertility to PCOS during in vitro fertilization. Journal of reproductive immunology 2020;138:103083. IF=3.993

30．Yang Z, Liu Z, Jiang S, Zeng J, Hu Y, Zhang G. Verification of needle guidance accuracy in pelvic phantom using registered ultrasound and MRI images for intracavitary/interstitial gynecologic brachytherapy. Journal of contemporary brachytherapy 2020;12:147-59. IF=1.788

31．Wang T, Hu Y*, He Y, Sun P and Guo Z. A retrospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Arch Gynecol Obstet 2019; 299: 1429-1435. （通讯作者）IF=2.493

32．Li N, He Y, Mi P and Hu Y*. ZNF582 methylation as a potential biomarker to predict cervical intraepithelial neoplasia type III/worse: A meta-analysis of related studies in Chinese population. Medicine (Baltimore) 2019; 98: e14297. 2019/02/09. （通讯作者）IF=1.817

33．Guo Z, Hu Y*., Yuan L, Li N and Wang T. A prospective study on the predictive value of DNA methylation in cervical intraepithelial neoplasia prognosis. Arch Gynecol Obstet 2018; 298: 589-596. （通讯作者）IF=2.493

34．Yuanjing Hu, Shuang Liang, Jianguo Zhao, Pengpeng Qu. Fertility-preserving treatment in three cases of placental sit trophoblastic tumor. European Journal of Gynaecological Oncology.2018;39(4):682-684.(第一作者) IF=0.255

35．何亚, 胡元晶* . p53和MMR联合检测在子宫内膜癌预后判断中的作用。Combination of MMR status and p53 status as the prognostic factor in endometrial carcinoma[J]. 现代妇产科进展, 2019，028(009):651-656. （通讯作者）

36．何亚, 王甜，胡元晶*. 子宫内膜癌分子分型特征及治疗价值的探讨[J]. 实用妇产科杂志, 2019, 035(007):505-508. （通讯作者）

科研项目

课题：

卵巢组织资源平台及生育力保护关键技术的建立，细胞生态海河实验室“揭榜挂帅”项目、HH22KYZX0024，2022.4—2024.12，300万元，合作者，在研。

子宫组织纸负载巨噬细胞促进子宫内膜组织再生的效应与机制研究，天津市教委重点项目，23JCZDJC00810，2023.1—2026.9，20万，第一完成人，在研。

3.联合单细胞和空间转录组学揭示早期子宫内膜癌淋巴脉管转移的细胞演变进程，津市科学技术局，2023YXZD06，2023.12—2026.11，20万，第一完成人，在研。

4. 前哨淋巴结超分期在中高危子宫内膜癌及宫颈癌的临床应用价值研究，国家临床重点专科专病队列项目，GJZDZKZBDL2022-012022/08-2025/07，20万元，第一完成人，在研。

 5. iRGD 修饰的纳米颗粒递送MCL-1 抑制剂在卵巢癌靶向治疗中的机制研究，天津市科技项目，20JCZXJC00010, 2020.10-2023.9，20万元，第一完成人，在研。

成果：

1.天津市卫生行业重点攻关项目：焦磷酸测序检测宿主抑癌基因甲基化与宫颈癌的相关性,成果登记号：津20181956（第一完成人）。

2.天津市科技重大专项与工程计划:遗传性非息肉性结直肠癌首发为子宫内膜癌的家系研究与早期诊断方法的开发和应用研究，成果登记号：17ZXMFSY00160（第一完成人)。

3.天津市重点研发计划科技支撑重点项目 面向高剂量内放疗的后装治疗系统研发，成果登记号：18YFZCSY01300（第二完成人)。

获奖情况

暂无

 

社会学术兼职

中国老年医学会妇科分会副会长、

中国妇幼保健协会青年委员会副主委、

中国抗癌协会妇科肿瘤专业委员会委员、

天津市医学会妇产科分会副主委、

天津市妇产科质量控制指导中心主委、

天津市医疗鉴定专家